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DatabaseWe have developed a graphical image database CancerProView (URL: http://cancerproview.dmb.med.keio.ac.
jp/php/cpv.html) to assist the search for alterations of the motifs/domains in the cancer-related proteins that
are caused by mutations in the corresponding genes. For the CancerProView, we have collected various kinds
of data on 180 cancer-related proteins in terms of the motifs/domains, genomic structures of corresponding
genes, and 109 charts of the protein interaction pathways. Moreover, we have collected the relevant data on
1041 reference genes including 197 non-cancer disease-associated genes, and the nucleotide sequences for 2011
full-length cDNA's and the alternatively spliced transcript variants. Thus, the CancerProView database system
would provide valuable information to facilitate basic cancer research aswell as for designing newmolecular di-
agnosis and drug discovery for cancers. The CancerProView database can be operated via Internet with anyWeb
browser, and the system is freely available to interested users without ID and password.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
To date, approximately 4500 genetic loci have been described as
distinct phenotypic features and genetic traits, many of which are
associatedwith various inherited disorders or sporadic genetic diseases.
Over 3000 genes have been identiﬁed as disease-causative genes and
molecularly cloned from particular regions of human chromosomes
[1]. Among them, at least 180 are considered to be cancer-related
genes, and over 50 of them are associated with familial cancers. These
cancer-related genes include members of “oncogenes” [2] and “tumor
suppressor genes” [3], whose protein products are often involved in
fundamental cellular functions, such as cell growth signal transduction
[4], DNA repair [5], cell adhesion [6] and so on.
Thanks to the human genome project, numerous databases have
been established for human genes and proteins to help understand
the molecular pathogenesis of human diseases, and many are publicly
made available. Two representatives of the comprehensive central
databases are OMIM (On line Mendelian Inheritance of Man) [1,7]
and HGMD (Human GeneMutation Database) [8]. The OMIM is a catalog
of ever increasing information on the association between human
characters (phenotype) and causative genes (genotype), providing
a morbid map of the human genome. The HGMD is a core collection
of human germline mutations in the nuclear genes that are associat-
ed with inherited disease. Databases specialized for particular dis-
eases such as cancer are also available. For example, COSMIC (Catalogue
of Somatic Mutations in Cancer) [http://www.sanger.ac.uk/cosmic]mizu).
rights reserved.provides information on the somatic mutations implicated in
human cancer [9] and KMcancerDB provides a highly sophisticated
display function for cancer-related gene mutations [10] as a sub-
database of MutationView [11].
To search for changes in the amino acid sequences of proteins, one
could access to the protein databases such as PIR International (PIR)
[12] and SWISS-PROT [13]. To search for the domains/motifs of pro-
teins, one could utilize several other databases such as PROSITE
[14], Pfam [15,16], SMART [17,18] and CDD [19]. Moreover, for pro-
tein interaction pathways, one can refer to BioCARTA (http://www.
biocarta.com/). The BioCARTA is a Web site that provides various
cell and molecular pathways of life as simpliﬁed diagrams. For meta-
bolic pathways, one can utilize KEGG (Kyoto Encyclopedia of Genes
and Genomes), which is a database that integrates genomic, chemi-
cal and systemic functional information [20]. These existing data-
bases provide valuable information on the nature of human genes and
proteins; however, none of themwas designed for the purpose of analyz-
ing the cancer-related proteins. Themost comprehensive database OMIM
provides a broad rangeof informationon cancer, but even in this one, data
on themolecular nature of cancer-protein are rather limited and only the
names of domain and motif are described [1]. Nonetheless, basic infor-
mation on the interaction pathways for cancer related-proteins is no
doubt indispensable for establishing relationship between mutations
and molecular pathogenesis of cancer. Hence, we decided to accomplish
systematic data collection of cancer-related genes/proteins, hoping that a
cancer-specialized database system would aid a broad range of basic re-
search and clinical applications, including the development of new mo-
lecular diagnosis and drug discovery for cancers.
In this study, we have constructed a graphical image database
system CancerProView (http://cancerproview.dmb.med.keio.ac.jp/
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data table format and data sources.Wewill also demonstrate how to ac-
cess to CancerProView and how typical search results are displayed
with a variety of graphic images. Many other features of CancerProView
will be discussed.2. Results
The CancerProView consists of 12 separate data table ﬁles (Fig. 1).
The system can be operated by three search keys “Gene symbol (a),
Protein ID (b) and Protein domain name (c)”. The gene symbol links
to ﬁve tables including “collected genes (#1), cancer-related genes
(#2), RefSeq sequencing ID (#3), gene symbol/trait (#4) and protein
interaction pathway images (#5)”. The RefSeq sequencing ID further
links to “protein name (#9) and protein domain (#10)” through the
protein ID. The ﬁle “protein domain name” consists of protein domain
(#10) and protein domain details (#11). The protein domain image
(#12) provides visualization of the mutations and polymorphisms
on the diagram of whole protein structure, which are constructed by
assembling the data on “protein domain (#10), OMIM allelic variants
(#6), protein sequences (#7) and cDNA sequences (#8)”.
Fig. 2 illustrates the front page of CancerProView. It provides the
“searchwindow” in threeways such as “Keyword search”, “Gene/Protein
search” and “Cancer types search”. Eachwindow offers quick entry to da-
tabase, and all the search results are instantly displayed onWeb browser.
To access CancerProView, one simply types in a favorite “keyword” or
“gene symbol” (Fig. 2). For example, typing-in “Breast cancer” brings
the results (Fig. 3), where 17 proteins/genes are shown, including
AKT1, BRCA1, BRCA2, KRAS, PIK3CA, RAD51, AR, BARD1, BRIP1, CASP8,
PALB2, PHB, RAD54L, RB1CC1, SLC22A18, TSG101, and XRCC3. It can
be immediately seen that some of these listed genes (CASP8, KRAS,
PALB2, FAD54L and XRCC3) are associated with various tumors other
than breast cancer. Clicking-on “Gene symbol” (e.g. BRCA1) brings
two image selectors “transcripts” or “protein pathways” (Fig. 3b).
Clicking-on “Transcripts” displays various molecular features (e.g.Fig. 1. The data ﬁle tables of CancerProView. The CancerProView has 12 data tables and sear
tein domain name (c)”. Gene symbol includes “collected genes (#1)”, “cancer-related Gen
action pathway image (#5)”. Protein ID includes “RefSeq sequencing ID”, “protein domain
(#10)” and “protein domain details (#11)”. Protein domain image (#12) are constructed from f
(#7)” and “cDNA sequences (#8)” by searching with protein ID and gene symbol as search key.BRCA1 in Fig. 4), and clicking-on “Pathways” provides a chart of protein
interaction pathway (e.g. BRCA1 in Fig. 3c).
One can click-on “All” (or “Cancer”) in the Gene/Protein search
window to bring a list of all 180 cancer-related genes or 1041 reference
genes. Then, choosing “BRCA1” brings “various molecular features of
BRCA1” on a diagram of protein domain structure, including gene
symbol, cDNA sequence (RefSeqID), amino acid sequence (Protein
ID) and protein name (Figs. 4a–c). Here, 5 isoforms of BRCA1 are dis-
played, including 4 truncated forms which lost certain domains.
These isoforms are predictable from the alternatively spliced vari-
ants of BRCA1 transcript. It is also evident that BRCA1 isoform 3
(NP_009228) retained two C-terminal BRCT domains but lost
N-terminal RING domain. Then, clicking-on “Gene symbol” brings the
data on “genetic mutation and polymorphism” (Fig. 5). Here, clicking-
on “BRCA1” in the top row shows mutation types of NP_009225 on the
list (Fig. 5a). Clicking-on “Image” shows the diagram of entire BRCA1
protein domain structure (Fig. 5b). Each domain can be expanded
to see details of mutation, where three out of four mutations are lo-
cated within the RING domain (long arrows in Fig. 5c). This sort of
analysis can be readily accomplished for each of 180 cancer-related
proteins.
Going back to Fig. 5 and clicking-on “RefSeq ID” or “Protein ID”
provides “cDNA sequence and protein amino acid sequence”
(Figs. 4a, b). Clicking-on “SMART protein domain structure” provides
“E-value of each domain” (Fig. 4c), by which one can evaluate if the
domain name “BRCT” is consensual or not (in this case, yes). Then,
clicking-on the domain “BRCT” brings a list of 20 cancer-related pro-
teins that possess BRCT domain in common (Fig. 6). These include
BARD1, LIG3, LIG4, REV1, XRCC1, BRCA1, MDC1, NBN, DBF4, RFC1,
TP53BP1 and their variants. Clicking-on “Gene symbol” brings a selec-
tion button to choose either “Transcripts”, “Pathways” or “Mutation
and Polymorphisms” (Fig. 6b). Furthermore, clicking-on “Protein ID”
or “Domain structure” brings the detailed information (Figs. 4b, c
and 5).
Going back to the “search window” and clicking-on “Domain, al-
phabetical” (Fig. 2d) provides a list of known protein domains inched via three main search keys namely “gene symbol (a)”, “protein ID (b)” and “pro-
es (#2)”, “RefSeq sequencing ID (#3)”, “Gene symbol/trait (#4)” and “protein inter-
(#9)” and “protein name (#10)”. Protein domain is linked to “protein domain name
our tables including “protein domain (#9)”, “OMIM allelic variants (#6)”, “protein sequences
Fig. 2. The search window of CancerProView. The upper left corner illustrates the front page of CancerProView providing three search windows, namely (1) Key word search, (2) Gene/Protein
search and (3) Cancer types search. TheGene/Protein searchparticularly provides three sub-entries such asGene Symbol (All or Cancer), All (proteins andpathways) and Protein domains (all or
alphabetical order) (Fig. 2 b–d). In thisﬁgure, the displaying places for the search results are indicatedwith long arrows. A partial list of cancer genes/proteins is shown after clicking “Disease” in
Cancer types search (f).
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with “B” are lined-up (Fig. 6c). Then, clicking-on BRCT brings a list
of the cancer-related proteins possessing the BRCT domain in com-
mon (Fig. 6a).
Clicking-on “All proteins” or “All Pathways” in the search window
(Fig. 2c) brings the entire list of protein variants (in total 2011) and
all charts of the cancer protein interaction pathways (in total 109), re-
spectively. Clicking-on a chart “BRCA1”provides an enlarged diagram
of theprotein interactionpathwayofBRCA1inassociationwithcell bi-
ological functions such as cell cycle events (Fig. 7). The chart clearly
shows that BRCA1 directly interacts with MDC1 and TP53BP1, but it
also indicates that many other proteins are associated with BRCA1
function. Interestingly, it can be seen that some proteins in the chart
are related to non-cancer diseases although exact meanings remain to
be elucidated. Then, clicking-on “BRCA1” brings the details of protein
BRCA1 as described in Fig. 5. Clinical and genetic information can be re-
trieved from OMIM via Internet by clicking “genetic trait/gene symbol
and disease name” on the chart (Figs. 7a, b), and reference also can be
retrieved from PubMed (Fig. 7c).
Clicking-on “Disease” in the search window (Fig. 2c) provides a list of
cancer types such as basal cell carcinoma, breast cancer, chondrosarcoma,
colon cancer, colionic adenoma and so on (Fig. 2f).
The CancerProView database can be operated via Internet with any
Web browser, and the system is freely available to interested users
without ID and password.3. Discussion
More than two decades ago (in 1991), we started construction of
a human gene database and made a prototype GeneView to graphi-
cally display the gene mapping information that were provided by
international genome database GDB (Genome Data Base). A few
years later (in 1995), we converted the GeneView to a more sophis-
ticated system MutationView (http://mutview.dmb.med.keio.ac.jp/)
to improve the operating function and to enhance the contents by
manually curating data from literatures and by extracting data
from the existing databases such as GDB, HUGO Gene Nomenclature
Committee, OMIM, HGMD and Pubmed. The MutationView utilizes
graphic display functions for both queries and results, and it has
been made available to the users without restriction. Since then,
we have been updating the mutation data on disease-related gene
mutations by a manual data collection. Signiﬁcant numbers of the
collected disease-genes in theMutationView were related to familial
cancers, so that we constructed a separate database MutationView/
KMcancerDB [10]. Several other databases are available for the
cancer-related genes (see Ref. [10]); however none of those was
designed for the purpose of analyzing the molecular natures of
cancer-related proteins. Hence, we constructed a specialized database
CancerProView as described in this study. The purpose of constructing
CancerProView was to add a new function to theMutationView to visu-
alize changes in the cancer-related proteins at a glance. Moreover, we
Fig. 3. The search result obtained by keyword “BREAST CANCER”. Typing-in “BREAST CANCER” brings 17 proteins/genes such as AKT1, BRCA1, BRCA2, KRAS, PIK3CA, RAD51, AR,
BARD1, BRIP1, CASP8, PALB2, PHB, RAD54L, RB1CC1, SLC22A18, TSG101, XRCC3. Clicking-on each gene brings the image selector for transcripts or protein pathways (Fig. 3b).
Clicking-on “Transcripts” displays the various molecular features (Fig. 4), and clicking-on “Pathways” brings charts of protein interaction pathways (Fig. 3c).
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collected relevant data from literature after careful evaluation although
other data sources are restricted mainly to OMIM and HGMD. We did
not use any data from the existing databases such as BioGRID [21],
STRING [22] and Reactome [23] because of following reasons. (1)
BioGRID is a database resource that includes over ten thousands interac-
tion attributes of proteins from various organisms. User-customized
graphs can be constructed with embedded protein, gene and interaction
attributes by a visualization system called Osprey, which is dynamically
linked to the BioGRID. BioGRID was published in 2006 after improving
Osprey [24] and GRID [25], which were made in 2003. We constructedFig. 4.Molecular features of BRCA1 gene and protein. Choosing “BRCA1” in Fig. 3 brings vari
diagram of protein domain structure. Clicking-on each item brings the relevant informationa prototype of CancerProView in 2002 to focus on the cancer-related pro-
teins, so that it was too late to change the data format. In fact, BioGRID is
an interesting prediction tool to illustrate possibly interacting proteins.
However, one needs to conﬁrm the reliability of outcome each time by re-
ferring to literature. (2) STRING is a tool to display a set of potentially
functionally associated genes/proteins by retrieving the genes that re-
peatedly occurs within clusters on the genome [22]. However, the
CancerProView was designed to collect experimentally proven data
by avoiding any predicted and unproven data. (3) Reactome is a curated
collection ofwell-documentedmolecular reactions, from simple interme-
diate metabolism such as sugar catabolism to complex cellular eventsous molecular features of BRCA1 such as Gene symbol, RefSeq ID, and Protein ID on the
(a, b, c).
Fig. 5. Themutation and polymorphism of BRCA1. Clicking-on “BRCA1” in the top row of Fig. 4 provides a mutation list of BRCA1 (NP_009225) (a, mutation list). Clicking-on “Image”
in the center of Fig. 5 provides the diagram of entire BRCA1 protein domain structure (b, whole image). Each domain can be expanded to see mutation details. Three out of four
mutations are seen within the RING domain (c, focused image).
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modates the data from KEGG and other databases. A semi-automated
procedure identiﬁes likely orthologous molecular reactions in mouse
and other model organisms, and display how one pathway interacts
with another. However, Reactome was not used for CancerProView toFig. 6. Twenty cancer-related proteins that possess BRCT as a common domain. Clicking-o
domain in common (a). Clicking-on gene symbol brings image selector (b) to choose “T
brings the relevant information (Fig. 4, Fig. 3c, Fig. 5). (c) The protein domains searched
(Fig. 2d) provides a list of all protein domains in alphabetical order, and if “B”was selected,
to Fig. 6a.keep our independent standpoint, yet all these databases are valuable
as supplementary tools.
The CancerProView provides fundamental information on cancer-
related proteins and their protein interaction pathway; hence we
believe it will be a useful tool for better understanding the basicn domain “BRCT” in Fig. 4c brings a list of cancer-related proteins that possess BRCT
ranscripts”, “Pathways” and “Mutations and Polymorphisms”. Clicking-on each item
by alphabetical order “B”. Clicking-on “Domain, alphabetical” in the search window
all such domains are lined-up (a partial list is shown). Clicking-on domain BRCT brings
Fig. 7. The protein interaction pathway for cancer-related protein BRCA1. Clicking-on “chart BRCA1” in Fig. 3c provides a diagram of protein interaction pathways. From the chart,
more detailed information can be obtained for (a) genetic trait or gene symbol (red gene symbol is disease-causative gene), (b) disease name and associated cell biological functions
such as cell cycle events and (c) reference.
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out as follows:
The CancerProView system was designed and constructed using
PHP program, so that it is easy to access through Web browser such
as Internet Explorer, FireFox and Safari. In the current CancerProView,
180 cancer-related genes and 1041 reference genes are registered,
and a list of the cancer-related genes/proteins can be displayed. The
registered numbers of the cancer-related genes are almost equivalent
to the current OMIM [1].
The diagrams showing molecular features of 180 cancer-related
proteins provide visual images in order to get hints for the relation
between domain alteration and loss or gain of protein functions. In
this connection, the search function “gene mutation and genetic poly-
morphism” gives supplementary information on the details of cancer-
related mutation in a given domain. It should be noteworthy that all
the cancer-related proteins possessing a particular domain in common
can be readily retrieved as a list, providing a basis to determine if and
how alteration in the same domain affects the function of different
disease-associated proteins and whether such domain alterations
generate a similar clinical phenotype. For this, the function key “domain,
alphabetical” helps quick search for those proteins.
The CancerProView provides 109 charts of the protein interaction
pathways for cancer-related proteins, showing valuable information
on the relevant proteins that are situated upstream or downstream of
metabolic and signaling pathways. In the chart, interesting ﬁndings
have been made such as that some cancer-related proteins are also as-
sociated with non-cancer disease (data not shown). Those proteins
could be considered as potential candidates for cancer-causative ones.
In such a way, CancerProView could be used as a tool for ﬁnding and
predicting potential cancer-causing genes/proteins.The power of CancerProView can be enhanced by using as a sup-
plementary tool of another database system KMcancerDB [10],
which deals speciﬁcally with the mutations in various cancer-
related genes. Thus, these two databases would provide useful in-
formation not only for basic and clinical cancer research but also
for designing new molecular diagnosis and better treatment of
cancers.
4. Material and methods
4.1. Data sources
We used the following data ﬁles: NCBI (“gene_info”: gene informa-
tion table, “gene2refseq”: Genbank gene/protein reference sequencing
ID table, “OMIM”: genetic disease database, “PubMed”: medical litera-
ture database), “HGMD”: human disease gene mutation database, and
“SMART” (include “Pfam”): protein domain search system.
4.2. Cancer-related genes and proteins
The candidates of “cancer-related genes” were retrieved from the
latest correspondence list “gene_info” of Locus Link at NCBI ftp site. It
consists of eight items including Locus ID, gene symbol, OMIM ID,
chromosome number, region, genetic trait, NCBI number and GDB
ID. We extracted “gene symbol” with OMIM ID, which was searched
from “genetic trait” of theOMIMusing keywords “Cancer”, “Oncogene”,
“Leukemia” and so on. The cancer-related gene was also searched with
“gene symbol” in the HGMD. If any relevant genes were found in both
OMIM and HGMD databases, they were considered as the cancer-
Table 1
The cancer-related genes in the current version of CancerProView.
Gene
symbol
Genetic trait Disease name OMIM
ID:
ABCA1 ATP-binding cassette, sub-family A (ABC1),
member 1
TANGIER DISEASE 600046
ACVR1B Activin A receptor, type IB PANCREATIC CARCINOMA 601300
AIP Aryl hydrocarbon receptor interacting protein PITUITARY ADENOMA 605555
AKT1 v-akt Murine thymoma viral oncogene homolog 1 BREAST CANCER 164730
ALK Anaplastic lymphoma receptor tyrosine kinase NEUROBLASTOMA,
SUSCEPTIBILITY TO, 3
105590
APC Adenomatous polyposis coli COLORECTAL CANCER,
GASTRIC CANCER,
ADENOMATOUS POLYPOSIS COLI,
611731
AR Androgen receptor BREAST CANCER 313700
AURKA Aurora kinase A COLON CANCER 603072
AXIN1 Axin 1 HEPATOCELLULAR CARCINOMA 603816
AXIN2 Axin 2 COLORECTAL CANCER 604025
BARD1 BRCA1 associated RING domain 1 BREAST CANCER 601593
BAX BCL2-associated X protein COLORECTAL CANCER 600040
BCL10 B-cell CLL/lymphoma 10 MALT LYMPHOMA 603517
BLM Bloom syndrome BLOOM SYNDROME 604610
BMPR1A Bone morphogenetic protein receptor,
type IA
JUVENILE POLYPOSIS SYNDROME 601299
BRAF v-raf Murine sarcoma viral oncogene homolog B1
Homolog B1
MALIGNANT MELANOMA,
COLON CANCER,
COLORECTAL CANCER,
NONSMALL CELL LUNG CANCER,
LUNG ADENOCARCINOMA,
NON-HODGKIN LYMPHOMA,
CARDIOFACIOCUTANEOUS SYNDROME
164757
BRCA1 Breast cancer 1, early onset BREAST–OVARIAN CANCER,
BREAST CANCER
113705
BRCA2 Breast cancer 2, early onset BREAST CANCER 2, EARLY-ONSET 600185
BRIP1 BRCA1 interacting protein C-terminal helicase 1 BREAST CANCER, FANCONI ANEMIA 605882
BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog
(yeast)
COLORECTAL CANCER
WITH CHROMOSOMAL INSTABILITY
602452
BUB1B BUB1 budding uninhibited by benzimidazoles
1 homolog beta (yeast)
COLORECTAL CANCER 602860
CASP10 Caspase 10, apoptosis-related cysteine
peptidase
AUTOIMMUNE
LYMPHOPROLIFERATIVE SYNDROME,
NON-HODGKIN LYMPHOMA,
GASTRIC CANCER
601762
CASP8 Caspase 8, apoptosis-related cysteine peptidase HEPATOCELLULAR CARCINOMA,
BREAST CANCER,
LUNG CANCER
601763
CBFB Core-binding factor, beta subunit ACUTE MYELOID LEUKEMIA M4EO SUBTYPE 121360
CCND1 Cyclin D1 VON HIPPEL–LINDAU DISEASE 168461
CDC73 Cell division cycle 73, Paf1/RNA polymerase II
complex component, homolog
(Saccharomyces cerevisiae)
HYPERPARATHYROIDISM–JAW
TUMOR SYNDROME
607393
CDH1 Cadherin 1, type 1, E-cadherin
(epithelial)
CADHERIN 1 192090
CDK4 Cyclin-dependent kinase 4 MELANOMA, CUTANEOUS MALIGNANT, 3 123829
CDKN1B Cyclin-dependent kinase inhibitor 1B
(p27, Kip1)
MULTIPLE ENDOCRINE NEOPLASIA,
TYPE IV
600778
CDKN2A Cyclin-dependent kinase inhibitor 2A
(melanoma, p16, inhibits CDK4)
MELANOMA 600160
CEBPA CCAAT/enhancer binding protein (C/EBP),
alpha
ACUTE MYELOID LEUKEMIA 116897
CHEK2 CHK2 checkpoint homolog
(Schizosaccharomyces pombe)
LI-FRAUMENI SYNDROME 604373
CHRNA3 Cholinergic receptor, nicotinic, alpha 3 LUNG CANCER 118503
CHRNA5 Cholinergic receptor, nicotinic, alpha 5 LUNG CANCER 118505
CSF1R Colony stimulating factor 1 receptor MYELOID MALIGNANCY 164770
CTNNB1 Catenin (cadherin-associated protein),
beta 1, 88 kDa
COLORECTAL CANCER,
HEPATOBLASTOMA,
HEPATOCELLULAR CARCINOMA,
PILOMATRICOMA,
OVARIAN CARCINOMA
116806
CYP2A6 Cytochrome P450, family 2,
subfamily A,
polypeptide 6
LUNG CANCER 122720
DCC Deleted in colorectal carcinoma COLORECTAL CANCER,
ESOPHAGEAL CARCINOMA
120470
DDB2 Damage-speciﬁc DNA binding protein 2,
48 kDa
XERODERMA PIGMENTOSUM,
COMPLEMENTATION GROUP E
600811
(continued on next page)
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Table 1 (continued)
Gene
symbol
Genetic trait Disease name OMIM
ID:
DLC1 Deleted in liver cancer 1 COLORECTAL CANCER 604258
DMBT1 Deleted in malignant brain tumors 1 GLIOBLASTOMA MULTIFORME 601969
EGFR Epidermal growth factor receptor
(erythroblastic leukemia viral
(v-erb-b) oncogene homolog, avian)
NONSMALL CELL LUNG CANCER 131550
EHBP1 EH domain binding protein 1 PROSTATE CANCER 609922
ELAC2 elaC homolog 2
(Escherichia coli)
PROSTATE CANCER 605367
EP300 E1A binding protein p300 COLORECTAL CANCER, RUBINSTEIN–TAYBI SYNDROME 602700
EPHB2 EPH receptor B2 PROGRESSION AND METASTASIS OF PROSTATE CANCER 600997
ERBB2 v-erb-b2 Erythroblastic leukemia viral
oncogene homolog 2, neuro/glioblastoma
derived oncogene homolog (avian)
ADENOCARCINOMA OF LUNG, GLIOBLASTOMA, GASTRIC
CANCER, OVARIAN CARCINOMA
164870
ERCC2 Excision repair cross-complementing
rodent repair deﬁciency,
complementation group 2
XERODERMA PIGMENTOSUM,
COMPLEMENTATION GROUP D
126340
ERCC3 Excision repair cross-complementing
rodent repair deﬁciency,
complementation group 3
(xeroderma pigmentosum
group B complementing)
XERODERMA PIGMENTOSUM B/COCKAYNE SYNDROME 133510
ERCC4 Excision repair cross-complementing rodent
repair deﬁciency, complementation group 4
XERODERMA PIGMENTOSUM, TYPE F 133520
ERCC5 Excision repair cross-complementing rodent
repair deﬁciency,
complementation group 5
XERODERMA PIGMENTOSUM,
COMPLEMENTATION GROUP G
133530
EXT1 Exostoses (multiple) 1 CHONDROSARCOMA, EXOSTOSES 608177
EXT2 Exostoses (multiple) 2 EXOSTOSES, MULTIPLE, TYPE II 608210
FAS Fas (TNF receptor superfamily,
member 6)
Fibroblast
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME,
TYPE IA,
SQUAMOUS CELL
CARCINOMA, BURN SCAR-RELATED
134637
FGF23 Fibroblast growth factor 23 HYPOPHOSPHATEMIC RICKETS, TUMORAL CALCINOSIS 605380
FGFR2 Fibroblast growth factor receptor 2 CROUZON SYNDROME 176943
FGFR3 ﬁbroblast growth factor receptor 3 ACHONDROPLASIA, THANATOPHORIC DYSPLASIA, TYPE I,
THANATOPHORIC DYSPLASIA,
TYPE II, HYPOCHONDROPLASIA, CROUZON SYNDROME
WITH ACANTHOSIS NIGRICANS,
MUENKE SYNDROME, SADDAN DYSPLASIA,
MULTIPLE MYELOMA,
COLORECTAL CANCER,
LADD SYNDROME, CAMPTODACTYLY, TALL STATURE
134934
FH Fumarate hydratase LEIOMYOMATOSIS AND RENAL CELL CANCER 136850
FLCN Folliculin BIRT–HOGG–DUBE SYNDROME, RENAL CARCINOMA 607273
GFAP Glial ﬁbrillary acidic protein ALEXANDER DISEASE, CHILDHOOD TYPE HEPATOCELLULAR
CARCINOMA,
137780
GNAI2 Guanine nucleotide binding protein
(G protein),
alpha inhibiting activity polypeptide 2
ADRENAL CORTICAL TUMOR 139360
GNAS GNAS complex locus PITUITARY TUMOR 139320
GPC3 Glypican 3 WILMS TUMOR, SIMPSON–GOLABI–BEHMEL SYNDROME 300037
HNF1A HNF1 homeobox A HEPATIC ADENOMA, MATURITY-ONSET DIABETES
OF THE YOUNG,
TYPE III
142410
HNF1B HNF1 homeobox B RENAL CYSTS AND DIABETES SYNDROME,
PROSTATE CANCER
189907
HRAS v-Ha-ras Harvey rat sarcoma viral oncogene
homolog
BLADDER CANCER, THYROID CARCINOMA,
COSTELLO SYNDROME
190020
IGF2R Insulin-like growth factor 2 receptor HEPATOCELLULAR CARCINOMA 147280
IL1B Interleukin 1, beta GASTRIC CANCER RISK AFTER H. PYLORI INFECTION 147720
IL1RN Interleukin 1 receptor antagonist GASTRIC CANCER RISK AFTER H. PYLORI INFECTION 147679
ING1 Inhibitor of growth family, member 1 SQUAMOUS CELL CARCINOMA 601566
IRF1 Interferon regulatory factor 1 GASTRIC CANCER, NONSMALL CELL LUNG CANCER 147575
JAK2 Janus kinase 2
(a protein tyrosine kinase)
POLYCYTHEMIA VERA, ACUTE MYELOGENOUS LEUKEMIA,
MYELOPROLIFERATIVE DISORDER
147796
KIF1B Kinesin family member 1B NEUROBLASTOMA, PHEOCHROMOCYTOMA,
CHARCOT-MARIE-TOOTH DISEASE
605995
KIT v-kit Hardy–Zuckerman 4 feline sarcoma
viral oncogene homolog
PIEBALDISM,
MAST CELL LEUKEMIA,
SYSTEMIC MAST
CELL DISEASE,
GASTROINTESTINAL
STROMAL TUMOR,
ACUTE MYELOID LEUKEMIA,
SPORADIC CHILDHOOD-ONSET
MASTOCYTOSIS, GERM CELL TUMOR
164920
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Gene
symbol
Genetic trait Disease name OMIM
ID:
KLF6 Kruppel-like factor 6 PROSTATE CANCER, GASTRIC CANCER 602053
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog LUNG CANCER, BLADDER CANCER,
GASTRIC CANCER,
BREAST CANCER, BREAST
ADENOCARCINOMA, PANCREATIC
CARCINOMA,
ACUTE MYELOGENOUS
MYELOGENOUS,
NOONAN SYNDROME 3,
CARDIOFACIOCUTANEOUS SYNDROME,
COSTELLO SYNDROME
190070
LEF1 Lymphoid enhancer-binding factor 1 SEBACEOUS TUMORS 153245
LHCGR Luteinizing hormone/choriogonadotropin receptor PRECOCIOUS PUBERTY, LEYDIG CELL
HYPOPLASIA
WITH MALE PSEUDOHERMAPHRODITISM
152790
MAD1L1 MAD1 mitotic arrest deﬁcient-like 1 (yeast) LYMPHOMA, PROSTATE CANCER 602686
MANF Mesencephalic astrocyte-derived neurotrophic factor PANCREATIC CANCER 601916
MCC Mutated in colorectal cancers COLORECTAL CANCER 159350
MDM2 Mdm2 p53 binding protein homolog (mouse) ACCELERATED TUMOR FORMATION 164785
MEN1 Multiple endocrine neoplasia I MULTIPLE ENDOCRINE NEOPLASIA, TYPE I,
CARCINOID TUMOR OF LUNG
131100
MET met proto-oncogene (hepatocyte growth factor receptor) PAPILLARY RENAL CELL CARCINOMA 2,
AUTISM 9
164860
MINPP1 Multiple inositol polyphosphate histidine phosphatase, 1 THYROID CARCINOMA 605391
MKL1 Megakaryoblastic leukemia (translocation) 1 MEGAKARYOBLASTIC LEUKEMIA 1 606078
MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) TURCOT SYNDROME,
HEREDITARY NONPOLYPOSIS COLORECTAL
CANCER TYPE 2, MUIR-TORRE SYNDROME
120436
MLH3 mutL homolog 3 (E. coli) COLORECTAL CANCER 604395
MLL Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) MYELOID/LYMPHOID OR MIXED
LINEAGE LEUKEMIA
159555
MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) HEREDITARY NONPOLYPOSIS
COLORECTAL CANCER TYPE 1,
MUIR-TORRE
SYNDROME, EARLY-ONSET GLIOBLASTOMA
609309
MSH3 mutS homolog 3 (E. coli) ENDOMETRIAL CANCER 600887
MSH6 mutS homolog 6 (E. coli) HEREDITARY NONPOLYPOSIS COLORECTAL
CANCER TYPE 5,
FAMILIAL ENDOMETRIAL CANCER
600678
MSMB Microseminoprotein, beta- PROSTATE CANCER 157145
MSR1 Macrophage scavenger receptor 1 PROSTATE CANCER 153622
MUTYH mutY homolog (E. coli) COLORECTAL ADENOMATOUS POLYPOSIS,
GASTRIC CANCER
604933
MXI1 MAX interactor 1 PROSTATE CANCER, NEUROFIBROSARCOMA 600020
MYC v-myc myelocytomatosis viral oncogene homolog
(avian)
BURKITT LYMPHOMA 190080
NBN nibrin NIJMEGEN BREAKAGE SYNDROME 602667
NDUFA13 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 THYROID CARCINOMA 609435
NF1 Neuroﬁbromin 1 NEUROFIBROMATOSIS, TYPE I 162200
NF2 Neuroﬁbromin 2 (merlin) NEUROFIBROMATOSIS, TYPE I 607379
NME1 Non-metastatic cells 1, protein (NM23A) expressed in NEUROBLASTOMA 156490
NPC1 Niemann–Pick disease, type C1 NIEMANN–PICK DISEASE 607623
NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog RECTAL CANCER, THYROID CARCINOMA,
AUTOIMMUNE
LYMPHOPROLIFERATIVE SYNDROME
164790
NTRK1 Neurotrophic tyrosine kinase, receptor, type 1 INSENSITIVITY TO PAIN, CONGENITAL,
WITH ANHIDROSIS,
THYROID CARCINOMA
191315
ODC1 Ornithine decarboxylase 1 COLONIC ADENOMA RECURRENCE 165640
OGG1 8-Oxoguanine DNA glycosylase RENAL CELL CARCINOMA 601982
OPCML Opioid binding protein/cell adhesion molecule-like EPITHELIAL OVARIAN CANCER 600632
PALB2 Partner and localizer of BRCA2 FANCONI ANEMIA, BREAST CANCER 610355
PALLD Palladin, cytoskeletal associated protein PANCREATIC CANCER 608092
PARK2 Parkinson disease (autosomal recessive, juvenile) 2, parkin PARKINSON DISEASE 2,
ADENOCARCINOMA OF LUNG
602544
PDGFB Platelet-derived growth factor beta polypeptide
(simian sarcoma viral (v-sis) oncogene homolog)
MENINGIOMA,
DERMATOFIBROSARCOMA
PROTUBERANS
190040
PDGFRA Platelet-derived growth factor receptor,
alpha polypeptide
GASTROINTESTINAL
STROMAL TUMOR,
HYPEREOSINOPHILIC SYNDROME
173490
PDGFRL Platelet-derived growth factor receptor-like COLORECTAL CANCER,
HEPATOCELLULAR CARCINOMA
604584
PHB Prohibitin BREAST CANCER 176705
PHOX2B Paired-like homeobox 2b CENTRAL HYPOVENTILATION SYNDROME, NEUROBLASTOMA 603851
(continued on next page)
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symbol
Genetic trait Disease name OMIM
ID:
PIK3CA Phosphoinositide-3-kinase, catalytic,
alpha polypeptide
BREAST CANCER, COLORECTAL CANCER,
OVARIAN CANCER
171834
PLA2G2A Phospholipase A2, group IIA
(platelets, synovial ﬂuid)
COLORECTAL CANCER 172411
PMS1 PMS1 postmeiotic segregation increased 1
(S. cerevisiae)
COLORECTAL CANCER 600258
PMS2 PMS2 postmeiotic segregation increased 2
(S. cerevisiae)
TURCOT SYNDROME, HEREDITARY NONPOLYPOSIS
COLORECTAL CANCER TYPE 4, SUPRATENTORIAL
PRIMITIVE NEUROECTODERMAL TUMORS
600259
POLH Polymerase (DNA directed), eta XERODERMA PIGMENTOSUM, VARIANT TYPE 603968
POU6F2 POU class 6 homeobox 2 WILMS TUMOR 609062
PPARG Peroxisome proliferator-activated
receptor gamma
OBESITY, DIABETES MELLITUS, COLON CANCER,
LIPODYSTROPHY,
GLIOBLASTOMA, INSULIN RESISTANCE,
LIPODYSTROPHY
601487
PPP2R1B Protein phosphatase 2
(formerly 2A),
regulatory subunit A, beta isoform
LUNG CANCER 603113
PRF1 Perforin 1 (pore forming protein) HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL,
2
170280
PRKAR1A Protein kinase, cAMP-dependent,
regulatory, type I, alpha
(tissue speciﬁc extinguisher 1)
CARNEY COMPLEX, TYPE 1, MYXOMA,
PIGMENTED NODULAR
ADRENOCORTICAL DISEASE, ADRENOCORTICAL TUMOR
188830
PRKCA Protein kinase C, alpha INVASIVE PITUITARY TUMOR 176960
PTCH1 Patched homolog 1 (Drosophila) BASAL CELL NEVUS SYNDROME,
BASAL CELL CARCINOMA,
HOLOPROSENCEPHALY 7
601309
PTCH2 Patched homolog 2 (Drosophila) MEDULLOBLASTOMA, BASAL CELL CARCINOMA,
BASAL CELL NEVUS SYNDROME
603673
PTEN Phosphatase and tensin homolog COWDEN DISEASE, LHERMITTE–DUCLOS DISEASE,
BANNAYAN–RILEY–RUVALCABA SYNDROME,
ENDOMETRIAL CARCINOMA, PROSTATE CANCER,
MALIGNANT MELANOMA,
OLIGODENDROGLIOMA,
SQUAMOUS CELL CARCINOMA,
PROTEUS SYNDROME,
PTEN HAMARTOMA TUMOR SYNDROME,
MACROCEPHALY/AUTISM
SYNDROME
601728
PTPN11 Protein tyrosine phosphatase,
non-receptor type 11
NOONAN SYNDROME 1 176876
PTPN12 Protein tyrosine phosphatase,
non-receptor type 12
COLON CANCER 600079
PTPRJ Protein tyrosine phosphatase,
receptor type, J
COLON CANCER 600925
RAD50 RAD50 homolog (S. cerevisiae) NIJMEGEN BREAKAGE SYNDROME 604040
RAD51 RAD51 homolog (RecA homolog,
E. coli) (S. cerevisiae)
BREAST CANCER, FAMILIAL 179617
RAD54B RAD54 homolog B (S. cerevisiae) LYMPHOMA, NON-HODGKIN , COLON CANCER 604289
RAD54L RAD54-like (S. cerevisiae) ADENOCARCINOMA, LYMPHOMA, NON-HODGKIN ,
BREAST CANCER
603615
RAF1 v-raf-1 murine leukemia viral
oncogene homolog 1
NOONAN SYNDROME 5, LEOPARD SYNDROME 2 164760
RASA1 RAS p21 protein activator
(GTPase activating protein) 1
BASAL CELL CARCINOMA, CAPILLARY
MALFORMATION-ARTERIOVENOUS MALFORMATION
139150
RB1 Retinoblastoma 1 RETINOBLASTOMA 180200
RB1CC1 RB1-inducible coiled-coil 1 BREAST CANCER 606837
RBBP8 Retinoblastoma binding protein 8 PANCREATIC CARCINOMA 604124
RET ret Proto-oncogene MULTIPLE ENDOCRINE NEOPLASIA TYPE IIA,
HIRSCHSPRUNG DISEASE,
FAMILIAL MEDULLARY THYROID CARCINOMA,
CONGENITAL CENTRAL
HYPOVENTILATION SYNDROME
164761
RNASEL Ribonuclease L
(2′,5′-oligoisoadenylate synthetase-dependent)
PROSTATE CANCER 180435
RNF139 Ring ﬁnger protein 139 RENAL CELL CARCINOMA 603046
RNF6 Ring ﬁnger protein
(C3H2C3 type) 6
ESOPHAGEAL SQUAMOUS CELL CARCINOMA 604242
RRAS2 Related RAS viral (r-ras)
oncogene homolog 2
OVARIAN CARCINOMA 600098
RUNX1 Runt-related transcription factor 1 FAMILIAL PLATELET DISORDER
WITH ASSOCIATED
MYELOID MALIGNANCY,
RHEUMATOID ARTHRITIS, TRANSIENT
MYELOPROLIFERATIVE DISORDER
OF DOWN SYNDROME
151385
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SDHB Succinate dehydrogenase complex, subunit B, iron sulfur (Ip) PARAGANGLIOMAS 4 185470
SDHC Succinate dehydrogenase complex,
subunit C,
integral membrane protein, 15 kDa
PARAGANGLIOMAS 3, PARAGANGLIOMA
AND GASTRIC STROMAL SARCOMA
602413
SDHD Succinate dehydrogenase complex, subunit D,
integral membrane protein
PARAGANGLIOMAS 1 602690
SLC22A18 Solute carrier family 22, member 18 BREAST CANCER, RHABDOMYOSARCOMA,
LUNG CANCER
602631
SMAD4 SMAD family member 4 PANCREATIC CARCINOMA 600993
SMAD7 SMAD family member 7 COLORECTAL CANCER 602932
SMARCB1 SWI/SNF related, matrix associated,
actin dependent regulator of chromatin,
subfamily b, member 1
MALIGNANT RHABDOID TUMOR,
BRAIN TUMOR,
SCHWANNOMATOSIS
601607
SMO Smoothened homolog
(Drosophila)
BASAL CELL CARCINOMA 601500
SOS1 Son of sevenless homolog 1
(Drosophila)
NOONAN SYNDROME 182530
SPRED1 Sprouty-related,
EVH1 domain containing 1
NEUROFIBROMATOSIS 609291
SRC v-src sarcoma
(Schmidt-Ruppin A-2)
viral oncogene homolog (avian)
ADVANCED COLON CANCER 190090
STX11 Syntaxin 11 HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,
FAMILIAL, 4
605014
SUFU Suppressor of fused homolog
(Drosophila)
MEDULLOBLASTOMA 607035
TG Thyroglobulin GOITER, FAMILIAL, WITH HYPOTHYROIDISM,
AUTOSOMAL RECESSIVE
188450
TGFBR2 Transforming growth factor,
beta receptor II
(70/80 kDa)
COLON CANCER, ESOPHAGEAL CANCER,
ESOPHAGEAL CANCER
190182
THRA Thyroid hormone receptor, alpha
(erythroblastic leukemia viral
(v-erb-a)
oncogene homolog, avian)
PITUITARY ADENOMA 190120
TLR2 Toll-like receptor 2 LEPROSY, COLORECTAL CANCER 603028
TLR4 Toll-like receptor 4 ENDOTOXIN HYPORESPONSIVENESS 603030
TNFRSF10B Tumor necrosis factor
receptor superfamily,
member 10b
SQUAMOUS CELL CARCINOMA 603612
TP53 Tumor protein p53 LI–FRAUMENI SYNDROME 1 191170
TSG101 Tumor susceptibility gene 101 BREAST CANCER 601387
TSHR Thyroid stimulating hormone receptor THYROID ADENOMA 603372
UNC13D unc-13 Homolog D
(Caenorhabditis elegans)
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,
FAMILIAL, 3
608897
VHL von Hippel–Lindau tumor suppressor VON HIPPEL–LINDAU SYNDROME,
RENAL CELL CARCINOMA,
HEMANGIOBLASTOMA,
PHEOCHROMOCYTOMA, ERYTHROCYTOSIS
608537
WRN Werner syndrome WERNER SYNDROME 604611
WT1 Wilms tumor 1 WAGR SYNDROME, DENYS–DRASH SYNDROME,
MESOTHELIOMA,
FRASIER SYNDROME,
MESANGIAL SCLEROSIS, MEACHAM SYNDROME
607102
WWOX WW domain containing oxidoreductase ESOPHAGEAL SQUAMOUS CELL CARCINOMA 605131
XPA Xeroderma pigmentosum, complementation group A XERODERMA PIGMENTOSUM,
COMPLEMENTATION GROUP A
611153
XPC Xeroderma pigmentosum, complementation group C XERODERMA PIGMENTOSUM,
COMPLEMENTATION GROUP C
278720
XRCC3 X-ray repair complementing defective repair
in Chinese hamster cells 3
MELANOMA, CUTANEOUS MALIGNANT,
BREAST CANCER
600675
ZFHX3 Zinc ﬁnger homeobox 3 PROSTATE CANCER 104155
ZMYM2 Zinc ﬁnger, MYM-type 2 STEM CELL LEUKEMIA/LYMPHOMA SYNDROME 602221
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genetic trait, gene locus and OMIM ID.4.3. Extraction of RefSeq ID
We searched for Locus ID in the gene_info by gene symbol and
extracted RefSeq ID from the correspondence list of Genbank RefSeq
(gene2refseq). Then, using RefSeq ID we constructed a list of 5 items(gene symbol, RefSeq cDNA ID, RefSeq amino acid sequence ID, cDNA se-
quence name, and amino acid sequence ﬁle name), providing the ﬁle (2).4.4. Protein domain and motif
The protein domain/motif was searched in SMART using RefSeq
amino acid sequences in the ﬁle (2), and the results provided the
list of predicted domain structure consisting of domain name, ﬁrst
92 S. Mitsuyama, N. Shimizu / Genomics 100 (2012) 81–92and end amino acid numbers of the domain, and E-value of the do-
main prediction, providing the ﬁle (3). These data were summarized
in the data ﬁle (4), and the detailed list of domain symbol and domain
name was made from Pfam and SMART, providing the ﬁle (5).
4.5. Building a relational database
We implemented the data in ﬁles (1), (2), (4) and (5) into the rela-
tional databaseMySQL. The data connectionwasmade by domain name
data ﬁles (4) and (5), and gene symbol data ﬁles (1), (2) and (4) (Fig. 1).
4.6. Protein interaction pathway in cancer cells
Documents for the cancer protein interaction pathway were
searched and retrieved from PubMed using tow keywords “gene symbol
and genetic trait”, and the collected diagramswere carefully redrawnas a
comprehensive chart to show interrelationship of these proteins in asso-
ciation with cell biological functions.
4.7. Disease-association in the protein interaction pathway
The cancer gene/protein list wasmade from the contents of OMIM by
distinguishing the difference between cancer and non-cancer diseases
(Table 1). In the cancer-related protein interaction pathways, any pro-
teins/genes related to non-cancer disease were indicated as red letters
and the corresponding disease name was adapted from OMIM.
4.8. Search windows and graphic display of search results
The searchwindow in the front page of database offers several entries
such as “keyword search, gene symbol, the list of all proteins, and the
alphabetical order of protein domains”. The search results are displayed
on Web browser using PHP program. Thus, CancerProView illustrates
the cancer protein interaction pathway, disease name, gene symbol
and protein domain, and literature. Detailed information of selected
disease can be displayed through OMIM. Gene mutation is graphically
displayed on the amino acid sequence of protein in reference to the
domain structure.
4.9. Inquiries
For any questions and comments, please contact SusumuMitsuyama
(mituyama@dmb.med.keio.ac.jp).
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